Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Sandra J. van Vliet, Juan J. Garcia-Vallejo, Sjoerd T.T. Schetters, Martino Ambrosini, Eelco D. Keuning, Rieneke van de Ven, Sophie K. Horrevorts, Sanne Duinkerken, Tanja D. de Gruijl, Hakan Kalay, Laura J.W. Kruijssen, Dorian A. Stolk, Yvette van Kooyk
Publikováno v:
Molecular Therapy: Oncolytics, Vol 21, Iss, Pp 315-328 (2021)
Stolk, D A, Horrevorts, S K, Schetters, S T T, Kruijssen, L J W, Duinkerken, S, Keuning, E, Ambrosini, M, Kalay, H, van de Ven, R, Garcia-Vallejo, J J, de Gruijl, T D, van Vliet, S J & van Kooyk, Y 2021, ' Palmitoylated antigens for the induction of anti-tumor CD8+ T cells and enhanced tumor recognition ', Molecular Therapy-Oncolytics, vol. 21, pp. 315-328 . https://doi.org/10.1016/j.omto.2021.04.009
Molecular Therapy-Oncolytics, 21, 315-328. Nature Publishing Group
Molecular Therapy Oncolytics
Stolk, D A, Horrevorts, S K, Schetters, S T T, Kruijssen, L J W, Duinkerken, S, Keuning, E, Ambrosini, M, Kalay, H, van de Ven, R, Garcia-Vallejo, J J, de Gruijl, T D, van Vliet, S J & van Kooyk, Y 2021, ' Palmitoylated antigens for the induction of anti-tumor CD8+ T cells and enhanced tumor recognition ', Molecular Therapy-Oncolytics, vol. 21, pp. 315-328 . https://doi.org/10.1016/j.omto.2021.04.009
Molecular Therapy-Oncolytics, 21, 315-328. Nature Publishing Group
Molecular Therapy Oncolytics
Induction of tumor-specific cytotoxic CD8+ T cells (CTLs) via immunization relies on the presentation of tumor-associated peptides in major histocompatibility complex (MHC) class I molecules by dendritic cells (DCs). To achieve presentation of exogen
Autor:
Arjan W. Griffioen, Peter Timmerman, Ruben S. A. Goedegebuure, Hans J. van der Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Madelon Q. Wentink
Publikováno v:
Oncologist, 26, 2, pp. e218-e229
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Lessons Learned The novel therapeutic vaccine hVEGF26–104/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF26–104/RFASE failed to induce seroconversion against native hVEGF165 and, accordingly, neither a decrease in cir
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha
Autor:
Hans van Vliet, Paul W. H. I. Parren, Rieneke van de Ven, Jana Vree, Roeland Lameris, Tanja D. de Gruijl, Renate de Boer, Anita G.M. Stam, George L. Scheffer, Arnon P. Kater, Steven T. Pals, Mark-David Levin, Rob C. Roovers, Iris de Weerdt
Publikováno v:
Cancer immunology research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicity.
Autor:
Hans van Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Lisa A. King, Roeland Lameris, Abdolkarim Sheikhi, Bruce Walcheck, Elisa C. Toffoli, Jan Spanholtz, Jurriaan B. Tuynman, Amanda A. van Vliet
Publikováno v:
Cancers
Volume 13
Issue 21
Toffoli, E C, Sheikhi, A, Lameris, R, King, L A, van Vliet, A, Walcheck, B, Verheul, H M W, Spanholtz, J, Tuynman, J, de Gruijl, T D & van der Vliet, H J 2021, ' Enhancement of nk cell antitumor effector functions using a bispecific single domain antibody targeting cd16 and the epidermal growth factor receptor ', Cancers, vol. 13, no. 21, 5446 . https://doi.org/10.3390/cancers13215446
Cancers, Vol 13, Iss 5446, p 5446 (2021)
Cancers, 13(21):5446. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13, 21
Volume 13
Issue 21
Toffoli, E C, Sheikhi, A, Lameris, R, King, L A, van Vliet, A, Walcheck, B, Verheul, H M W, Spanholtz, J, Tuynman, J, de Gruijl, T D & van der Vliet, H J 2021, ' Enhancement of nk cell antitumor effector functions using a bispecific single domain antibody targeting cd16 and the epidermal growth factor receptor ', Cancers, vol. 13, no. 21, 5446 . https://doi.org/10.3390/cancers13215446
Cancers, Vol 13, Iss 5446, p 5446 (2021)
Cancers, 13(21):5446. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13, 21
Simple Summary Strategies to enhance the preferential accumulation and activation of Natural Killer (NK) cells in the tumor microenvironment can be expected to increase the efficacy of NK cell-based cancer immunotherapy. In this study, we report that
Autor:
Koen Van de Vijver, Anne Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Jossie Rotman, Gemma G. Kenter, Guus Fons, H. J. M. A. A. Zijlmans, Ekaterina J Jordanova
Publikováno v:
Journal for Immunotherapy of Cancer, 9(10):e003623. BioMed Central
Heeren, A M, Rotman, J, Samuels, S, Zijlmans, H J M A A, Fons, G, Van De Vijver, K K, Bleeker, M C G, Kenter, G G, Jordanova, E J & De Gruijl, T D 2021, ' Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth ', Journal for Immunotherapy of Cancer, vol. 9, no. 10, e003623 . https://doi.org/10.1136/jitc-2021-003623
Journal for immunotherapy of cancer, 9(10):e003623. BioMed Central Ltd.
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Heeren, A M, Rotman, J, Samuels, S, Zijlmans, H J M A A, Fons, G, Van De Vijver, K K, Bleeker, M C G, Kenter, G G, Jordanova, E J & De Gruijl, T D 2021, ' Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth ', Journal for Immunotherapy of Cancer, vol. 9, no. 10, e003623 . https://doi.org/10.1136/jitc-2021-003623
Journal for immunotherapy of cancer, 9(10):e003623. BioMed Central Ltd.
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
JOURNAL FOR IMMUNOTHERAPY OF CANCER
BackgroundTherapeutic immune intervention is highly dependent on the T-cell priming and boosting capacity of tumor-draining lymph nodes (TDLN). In vulvar cancer, in-depth studies on the immune status of (pre)metastatic TDLN is lacking.MethodsWe have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a549388d783f72acec6d84918181b5a0
https://research.vumc.nl/en/publications/7f5455c0-d175-4438-95ce-eade7181a18a
https://research.vumc.nl/en/publications/7f5455c0-d175-4438-95ce-eade7181a18a
Autor:
Latifa Elantak, Iris A. Schulkens, Arjan W. Griffioen, Pauline Touarin, Ulf J. Nilsson, Kitty C. M. Castricum, Tanja D. de Gruijl, Hakon Lefler, Victor L. Thijssen, Roy Heusschen, Lucia Sanjurjo, Ed Aanhane, Rory R. Koenen
Galectins are versatile glycan-binding proteins involved in immunomodulation. Increasing evidence suggests that galectins can control the immunoregulatory function of cytokines and chemokines through direct binding. Here, we report a new inverse mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b52d83da78edd60bbd8a58755ac95ad4
https://doi.org/10.21203/rs.3.rs-275662/v1
https://doi.org/10.21203/rs.3.rs-275662/v1
Autor:
Roeland Lameris, Esther Drent, Tanja D. de Gruijl, Hans van Vliet, Afroditi Katsarou, Renée Poels, Tuna Mutis, Maria Themeli, Niels W.C.J. van de Donk
Publikováno v:
International Journal of Molecular Sciences, 22(3):1096, 1-16. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences
Poels, R, Drent, E, Lameris, R, Katsarou, A, Themeli, M, van der Vliet, H J, de Gruijl, T D, van de Donk, N W C J & Mutis, T 2021, ' Preclinical evaluation of invariant natural killer t cells modified with cd38 or bcma chimeric antigen receptors for multiple myeloma ', International Journal of Molecular Sciences, vol. 22, no. 3, 1096, pp. 1-16 . https://doi.org/10.3390/ijms22031096
International Journal of Molecular Sciences, Vol 22, Iss 1096, p 1096 (2021)
Volume 22
Issue 3
International Journal of Molecular Sciences
Poels, R, Drent, E, Lameris, R, Katsarou, A, Themeli, M, van der Vliet, H J, de Gruijl, T D, van de Donk, N W C J & Mutis, T 2021, ' Preclinical evaluation of invariant natural killer t cells modified with cd38 or bcma chimeric antigen receptors for multiple myeloma ', International Journal of Molecular Sciences, vol. 22, no. 3, 1096, pp. 1-16 . https://doi.org/10.3390/ijms22031096
International Journal of Molecular Sciences, Vol 22, Iss 1096, p 1096 (2021)
Volume 22
Issue 3
Due to the CD1d restricted recognition of altered glycolipids, V&alpha
24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-th
24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1323972809fe1d5a315d714675b0887b
https://research.vumc.nl/en/publications/66121505-9a17-4c58-a331-f06003f15d8f
https://research.vumc.nl/en/publications/66121505-9a17-4c58-a331-f06003f15d8f
Autor:
Martino Ambrosini, Sanne Duinkerken, Juan J. Garcia-Vallejo, Tanja D. de Gruijl, Lisa Rutte, Hakan Kalay, Sophie K. Horrevorts, Yvette van Kooyk
Publikováno v:
Duinkerken, S, Horrevorts, S K, Kalay, H, Ambrosini, M, Rutte, L, de Gruijl, T D, Garcia-Vallejo, J J & van Kooyk, Y 2019, ' Glyco-dendrimers as intradermal anti-tumor vaccine targeting multiple skin DC subsets ', Theranostics, vol. 9, no. 20, pp. 5797-5809 . https://doi.org/10.7150/thno.35059
Theranostics, 9, 5797-5809
Theranostics
Theranostics, 9(20), 5797-5809. Ivyspring International Publisher
Theranostics, 9, 20, pp. 5797-5809
Theranostics, 9, 5797-5809
Theranostics
Theranostics, 9(20), 5797-5809. Ivyspring International Publisher
Theranostics, 9, 20, pp. 5797-5809
Contains fulltext : 215802.pdf (Publisher’s version ) (Open Access) The human skin is an attractive anti-tumor vaccination site due to the vast network of dendritic cell (DC) subsets that carry antigens to the draining lymph nodes and stimulate tum
Autor:
Hans van Vliet, Pita de Kok, Mahsa Yazdanpanah-Samani, Yannick D. Höppner, Abdolkarim Sheikhi, Henk M.W. Verheul, Jan Spanholtz, Elisa C. Toffoli, Tanja D. de Gruijl
Publikováno v:
Toffoli, E C, Sheikhi, A, Höppner, Y D, de Kok, P, Yazdanpanah-Samani, M, Spanholtz, J, Verheul, H M W, van der Vliet, H J & de Gruijl, T D 2021, ' Natural killer cells and anti-cancer therapies : Reciprocal effects on immune function and therapeutic response ', Cancers, vol. 13, no. 4, 711, pp. 1-27 . https://doi.org/10.3390/cancers13040711
Cancers
Cancers, 13, 4
Cancers, Vol 13, Iss 711, p 711 (2021)
Cancers, 13
Cancers
Cancers, 13, 4
Cancers, Vol 13, Iss 711, p 711 (2021)
Cancers, 13
Simple Summary Natural Killer (NK) cells are innate lymphocytes that play an important role in the immune response against cancer. Their activity is controlled by a balance of inhibitory and activating receptors, which in cancer can be skewed to favo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4155f63557a4bd14e24d31b33f90b38a
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232069
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232069